Literature DB >> 26687645

Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo.

Yan Liu1, Tingting Bi2, Wei Dai1, Gang Wang1, Liqiang Qian1, Quangen Gao3, Genhai Shen4.   

Abstract

Oxymatrine (OMT), one of the main active components of extracts from the dry roots of Sophora flavescens, has long been employed clinically to treat cancers. Here, we investigated the synergistic effect of OMT with 5-fluorouracil (5-Fu) on the tumor growth inhibition of hepatocellular carcinoma cells (HCC; Hep-G2 and SMMC-7721) and explored the underlying mechanism. Cells were treated with OMT and/or 5-Fu and subjected to cell viability, colony formation, apoptosis, cell cycle, western blotting, xenograft tumorigenicity assay, and immunohistochemistry. OMT and 5-Fu inhibited the proliferation of Hep-G2 and SMMC-7721 cells, and combination treatment with OMT and 5-Fu resulted in a combination index <1, indicating a synergistic effect. Co-treatment with OMT and 5-Fu caused G0/G1 phase arrest by upregulating P21 and P27 and downregulating cyclin D, and induced apoptosis through increasing the production of reactive oxygen species (ROS) and decreasing the levels of p-ERK. In addition, the inhibition of ROS respectively reversed the cell death induced by 5-Fu + OMT, suggesting the key roles of ROS in the process. More importantly, 5-Fu and OMT in combination exhibit much superior tumor weight and volume inhibition on SMMC-7721 xenograft mouse model in comparison to 5-Fu or OMT alone. Immunohistochemistry analysis suggests the combinations greatly suppressed tumor proliferation, which was consistent with our in vitro results. Taken together, our findings indicated that OMT sensitizes HCC to 5-Fu treatment by the suppression of ERK activation through the overproduction of ROS, and combination treatment with OMT and 5-Fu would be a promising therapeutic strategy for HCC treatment.

Entities:  

Keywords:  5-Fluorouracil; Hepatocellular carcinoma; Oxymatrine; ROS

Mesh:

Substances:

Year:  2015        PMID: 26687645     DOI: 10.1007/s13277-015-4642-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  40 in total

1.  Downregulation of tNASP inhibits proliferation through regulating cell cycle-related proteins and inactive ERK/MAPK signal pathway in renal cell carcinoma cells.

Authors:  Jianzheng Fang; Hainan Wang; Wei Xi; Gong Cheng; Shangqian Wang; Shifeng Su; Shengli Zhang; Yunfei Deng; Zhen Song; Aiming Xu; Bianjiang Liu; Jingyi Cao; Zengjun Wang
Journal:  Tumour Biol       Date:  2015-02-12

Review 2.  Traditional Chinese medicine and related active compounds against hepatitis B virus infection.

Authors:  Xiaoyan Cui; Yueling Wang; Norihiro Kokudo; Dingzhi Fang; Wei Tang
Journal:  Biosci Trends       Date:  2010-04       Impact factor: 2.400

3.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Authors:  S Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; C Focan; P Chollet; J F Llory; Y Letourneau; B Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; R Adam; J L Misset; F Lévi
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

4.  Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma.

Authors:  Yang Hyun Baek; Kyoung Tae Kim; Sung Wook Lee; Jin Sook Jeong; Byeong Ho Park; Kyung Jin Nam; Jin Han Cho; Young Hoon Kim; Young Hoon Roh; Hyung Sik Lee; Young Min Choi; Sang Young Han
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

5.  Matrine induces caspase-dependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2.

Authors:  Cheng Zhen Liang; Jia Kai Zhang; Zhongli Shi; Bing Liu; Chengchun Q Shen; Hui Min Tao
Journal:  Cancer Chemother Pharmacol       Date:  2011-06-30       Impact factor: 3.333

6.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

7.  Oxymatrine downregulates TLR4, TLR2, MyD88, and NF-kappaB and protects rat brains against focal ischemia.

Authors:  Hongguang Fan; Litao Li; Xiangjian Zhang; Ying Liu; Chenhui Yang; Yi Yang; Jing Yin
Journal:  Mediators Inflamm       Date:  2010-02-16       Impact factor: 4.711

Review 8.  Adhesion-mediated apoptosis resistance in cancer.

Authors:  Mike-Andrew Westhoff; Simone Fulda
Journal:  Drug Resist Updat       Date:  2009-09-01       Impact factor: 18.500

9.  Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases.

Authors:  Yuan Yan; Jie Li; Jia Han; Ni Hou; Ying Song; Lei Dong
Journal:  Anticancer Drugs       Date:  2015-06       Impact factor: 2.248

10.  Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling.

Authors:  Cundong Fan; Wenjie Zheng; Xiaoyan Fu; Xiaoling Li; Yum-Shing Wong; Tianfeng Chen
Journal:  Oncotarget       Date:  2014-05-15
View more
  8 in total

1.  Lupeol enhances inhibitory effect of 5-fluorouracil on human gastric carcinoma cells.

Authors:  Yan Liu; Tingting Bi; Wei Dai; Gang Wang; Liqiang Qian; Genhai Shen; Quangen Gao
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-02-19       Impact factor: 3.000

2.  Investigation of copper-cysteamine nanoparticles as a new photosensitizer for anti-hepatocellular carcinoma.

Authors:  Xuejing Huang; Fengjie Wan; Lun Ma; Jonathan B Phan; Rebecca Xueyi Lim; Cuiping Li; Jiagui Chen; Jinghuan Deng; Yasi Li; Wei Chen; Min He
Journal:  Cancer Biol Ther       Date:  2019-02-06       Impact factor: 4.742

3.  Oxymatrine Synergistically Enhances Doxorubicin Anticancer Effects in Colorectal Cancer.

Authors:  Di Pan; Wen Zhang; Nenling Zhang; Yini Xu; Yi Chen; Jianqing Peng; Yan Chen; Yanyan Zhang; Xiangchun Shen
Journal:  Front Pharmacol       Date:  2021-06-30       Impact factor: 5.810

4.  Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway.

Authors:  Wei Li; Xinfang Yu; Shiming Tan; Wenbin Liu; Li Zhou; Haidan Liu
Journal:  Cancer Med       Date:  2017-12-13       Impact factor: 4.452

5.  Oxymatrine exerts protective effects on osteoarthritis via modulating chondrocyte homoeostasis and suppressing osteoclastogenesis.

Authors:  Yafei Jiang; Weilin Sang; Cong Wang; Haiming Lu; Tao Zhang; Zhuoying Wang; Yu Liu; Bao Xue; Song Xue; Zhengdong Cai; Yingqi Hua; Libo Zhu; Jinzhong Ma
Journal:  J Cell Mol Med       Date:  2018-05-25       Impact factor: 5.295

Review 6.  Recent Advances in Herbal Medicines for Digestive System Malignancies.

Authors:  Jiyao Sheng; Xiaohan Zou; Ziqian Cheng; Yien Xiang; Wei Yang; Yang Lin; Ranji Cui
Journal:  Front Pharmacol       Date:  2018-11-20       Impact factor: 5.810

7.  Oxymatrine Synergistically Potentiates the Antitumor Effects of Cisplatin in Human Gastric Cancer Cells.

Authors:  Yan Liu; Lei Qin; Tingting Bi; Wei Dai; Wei Liu; Quangen Gao; Genhai Shen
Journal:  J Cancer       Date:  2018-10-31       Impact factor: 4.207

8.  Synergistic effects of CP-25 and 5-fluorouracil on the hepatocellular carcinoma in vivo and in vitro through regulating activating mitochondrial pathway.

Authors:  Wei Chang; Xiao-Pei Jiang; Shuai Jin; Pei-Pei Li; Sha-Sha Song; Ping-Fan Yuan; Wei Wei; Jing-Tao Lu
Journal:  J Cancer       Date:  2022-01-04       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.